The discrepancy at T2 (between theoretical upper Hb targets for specific risk groups and actual upper Hb targets at baseline) is particularly interesting given the apparent widespread adoption of KDIGO guidelines at this time point, which include probably the clearest recommendations yet on differential anaemia management. This evidence concerns the gene GSTM1 and anemia.